Business
BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical Programs and Enhance Value Creation
Focusing on lead programs BI-1206 and BI-1808, with strong clinical data and upcoming value-creation milestones Phase 2a study of BI-1206 in combination with pembrolizumab in first-line NSCLC to initiate in H2 2025 LUND, SE / ACCESS Newswire / August ...
About this update from Bioinvent International Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"Focusing on lead programs BI-1206 and BI-1808, with strong clinical data and upcoming value-creation milestones","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2a study of BI-1206 in combination with pembrolizumab in first-line NSCLC to initiate in H2 2025","length":102,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":213,"olType":false},{"type":"text","content":"LUND, SE / ACCESS Newswire / August 26, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced a strategic portfolio optimization initiative to maximize the probability of success for its lead clinical programs and optimize resource allocation across its portfolio, with an intensified focus on our most promising clinical assets.","length":516,"tagName":"p"},{"type":"text","content":"Following a comprehensive strategic review, BioInvent will concentrate resources on advancing BI-1808, its first-in-class anti-TNFR2 antibody, currently in Phase 2a clinical development in solid cancer and cutaneous T-cell lymphoma (CTCL), as well as BI-1206, an FcyRIIB-blocking antibody, currently in Phase 2a in non-Hodgkin's lymphoma (NHL), and starting a Phase 2a trial in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC). As part of this strategy, BioInvent will pause the development of Phase 1 programs for BI-1910 and BI-1607. Development of the oncolytic virus BT-001 will be pursued in an investigator-led trial in collaboration with Transgene. This refined focus is designed to accelerate the lead programs towards key clinical milestones and strengthen their pathway towards regulatory approval while ensuring operational excellence.","length":889,"tagName":"p"},{"type":"text","content":""This is an important next step for BioInvent," said Martin Welschof, Chief Executive Officer of BioInvent. "We are sharpening our clinical focus on our most advanced assets with the greatest potential impact and multiple upcoming catalysts, thus maintaining a strong foundation for future growth. Our decision reflects a disciplined, opportunity-driven approach that we believe will maximize both patien...